Christian Gratzke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9129863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European Urology, 2015, 67, 1099-1109.	1.9	735
2	A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. European Urology, 2015, 67, 1066-1096.	1.9	596
3	Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 445-475.	0.6	314
4	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 181-191.	10.7	263
5	Techniques and Long-Term Results of Surgical Procedures for BPH. European Urology, 2006, 49, 970-978.	1.9	254
6	68Ca-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European Urology, 2016, 70, 553-557.	1.9	248
7	Complications and Early Postoperative Outcome After Open Prostatectomy in Patients With Benign Prostatic Enlargement: Results of a Prospective Multicenter Study. Journal of Urology, 2007, 177, 1419-1422.	0.4	244
8	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology, 2015, 68, 980-992.	1.9	206
9	⁶⁸ Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 1720-1725.	5.0	179
10	Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study. European Urology, 2015, 68, 643-652.	1.9	176
11	Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget, 2017, 8, 3581-3590.	1.8	172
12	Role of Radical Prostatectomy in Metastatic Prostate Cancer: Data from the Munich Cancer Registry. European Urology, 2014, 66, 602-603.	1.9	158
13	The "All-Seeing Needleâ€: Initial Results of an Optical Puncture System Confirming Access in Percutaneous Nephrolithotomy. European Urology, 2011, 59, 1054-1059.	1.9	152
14	Prostatic urethral lift vs transurethral resection of the prostate: 2â€year results of the <scp>BPH</scp> 6 prospective, multicentre, randomized study. BJU International, 2017, 119, 767-775.	2.5	152
15	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. European Urology, 2016, 69, 788-794.	1.9	140
16	Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nature Reviews Urology, 2007, 4, 368-378.	1.4	123
17	Prospective Evaluation of the Functional Sling Suspension for Male Postprostatectomy Stress Urinary Incontinence: Results after 1 Year. European Urology, 2009, 56, 928-933.	1.9	123
18	Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephronâ€sparing surgery in patients with renal cell carcinoma. BJU International, 2009, 104, 470-475.	2.5	117

#	Article	IF	CITATIONS
19	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
20	A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. European Urology, 2009, 56, 810-820.	1.9	107
21	Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer. World Journal of Urology, 2020, 38, 2329-2347.	2.2	105
22	A Mutation in the Inner Mitochondrial Membrane Peptidase 2-Like Gene (Immp2l) Affects Mitochondrial Function and Impairs Fertility in Mice1. Biology of Reproduction, 2008, 78, 601-610.	2.7	102
23	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. European Urology, 2019, 75, 176-183.	1.9	101
24	Complications of the AdVance Transobturator Male Sling in the Treatment of Male Stress Urinary Incontinence. Urology, 2010, 75, 1494-1498.	1.0	100
25	Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013, 64, 228-243.	1.9	97
26	The role of the transient receptor potential (TRP) superfamily of cationâ€selective channels in the management of the overactive bladder. BJU International, 2010, 106, 1114-1127.	2.5	95
27	[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard – Implications for focal radiotherapy planning in primary prostate cancer. Radiotherapy and Oncology, 2019, 141, 214-219.	0.6	83
28	Regional, age and gender differences in architectural measures of bone quality and their correlation to bone mechanical competence in the human radius of an elderly population. Bone, 2009, 45, 882-891.	2.9	80
29	Preliminary Results on the Off-Label Use of Duloxetine for the Treatment of Stress Incontinence after Radical Prostatectomy or Cystectomy. European Urology, 2006, 49, 1075-1078.	1.9	78
30	Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY) Tj ETQq	0 0 10 rgBT	/Onserlock 10
31	Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical Cystectomy. European Urology, 2011, 59, 712-718.	1.9	76
32	Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: A prospective single-center study. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 55-59.	1.6	75
33	Laser Therapy for Upper Urinary Tract Transitional Cell Carcinoma: Indications and Management. European Urology, 2009, 56, 65-71.	1.9	70
34	Transient Receptor Potential A1 (TRPA1) Activity in the Human Urethra—Evidence for a Functional Role for TRPA1 in the Outflow Region. European Urology, 2009, 55, 696-704.	1.9	69
35	The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. European Urology, 2011, 60, 94-105.	1.9	66
36	A Systematic Review of Patients' Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. European Urology, 2021, 79, 796-809.	1.9	65

#	Article	IF	CITATIONS
37	Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. European Urology, 2017, 71, 391-402.	1.9	64
38	Current Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 904-916.	1.9	62
39	In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urological Research, 2007, 35, 49-54.	1.5	61
40	Prostatic α1â€adrenoceptors: New concepts of function, regulation, and intracellular signaling. Neurourology and Urodynamics, 2014, 33, 1074-1085.	1.5	60
41	Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. European Urology, 2017, 72, 986-997.	1.9	60
42	The Diode Laser: A Novel Side-Firing Approach for Laser Vaporisation of the Human Prostate—Immediate Efficacy and 1-Year Follow-Up. European Urology, 2007, 52, 1717-1722.	1.9	59
43	Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. European Urology, 2017, 72, 757-769.	1.9	59
44	Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer and Prostatic Diseases, 2022, 25, 256-263.	3.9	58
45	Plasma Vaporisation of the Prostate: Initial Clinical Results. European Urology, 2010, 57, 693-698.	1.9	57
46	Effects of Cannabinor, a Novel Selective Cannabinoid 2 Receptor Agonist, on Bladder Function in Normal Rats. European Urology, 2010, 57, 1093-1100.	1.9	55
47	Organâ€preserving neodymiumâ€yttriumâ€aluminiumâ€garnet laser therapy for penile carcinoma: a longâ€term followâ€up. BJU International, 2010, 106, 786-790.	2.5	55
48	Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 508-514.	1.6	55
49	Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current Evidence. European Urology, 2011, 60, 527-535.	1.9	52
50	High-level virtual reality simulator for endourologic procedures of lower urinary tract. Urology, 2006, 67, 1144-1148.	1.0	50
51	Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 295-301.	1.6	50
52	Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013, 64, 610-621.	1.9	50
53	Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). European Urology Focus, 2019, 5, 1022-1028.	3.1	48
54	High-power diode laser at 980Ânm for the treatment of benign prostatic hyperplasia: exÂvivo investigations on porcine kidneys and human cadaver prostates. Lasers in Medical Science, 2009, 24, 172-178.	2.1	47

#	Article	IF	CITATIONS
55	Early Catheter Removal after Robot-assisted Radical Prostatectomy: Surgical Technique and Outcomes for the Aalst Technique (ECaRemA Study). European Urology, 2016, 69, 917-923.	1.9	47
56	Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. European Urology, 2019, 75, 788-798.	1.9	46
57	Expression of Fatty Acid Amide Hydrolase (FAAH) in Human, Mouse, and Rat Urinary Bladder and Effects of FAAH Inhibition on Bladder Function in Awake Rats. European Urology, 2012, 61, 98-106.	1.9	45
58	The PolyScope: A Modular Design, Semidisposable Flexible Ureterorenoscope System. Journal of Endourology, 2010, 24, 1061-1066.	2.1	44
59	Information on surgical treatment of benign prostatic hyperplasia on YouTube is highly biased and misleading. BJU International, 2020, 125, 595-601.	2.5	44
60	Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2Âyears. World Journal of Urology, 2019, 37, 1353-1360.	2.2	43
61	Transient Receptor Potential A1 and Cannabinoid Receptor Activity in Human Normal and Hyperplastic Prostate: Relation to Nerves and Interstitial Cells. European Urology, 2010, 57, 902-910.	1.9	42
62	Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	1.8	41
63	Delaying Surgical Treatment of Penile Fracture Results in Poor Functional Outcomes: Results from a Large Retrospective Multicenter European Study. European Urology Focus, 2018, 4, 106-110.	3.1	39
64	Current Treatment for Benign Prostatic Hyperplasia. Deutsches Ärzteblatt International, 2020, 117, 843-854.	0.9	38
65	Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1987-1997.	6.4	37
66	Clinical and technical aspects of bipolar transurethral prostate resection. Scandinavian Journal of Urology and Nephrology, 2008, 42, 318-323.	1.4	35
67	"Finding the needle in a haystack― oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World Journal of Urology, 2017, 35, 1777-1782.	2.2	35
68	Positive urine cytology but negative whiteâ€light cystoscopy: an indication for fluorescence cystoscopy?. BJU International, 2009, 103, 484-487.	2.5	34
69	What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction?. European Urology Focus, 2019, 5, 351-356.	3.1	34
70	Knee Cartilage Morphologic Characteristics and Muscle Status of Professional Weight Lifters and Sprinters. American Journal of Sports Medicine, 2007, 35, 1346-1353.	4.2	33
71	Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scandinavian Journal of Urology, 2017, 51, 130-136.	1.0	33
72	Radiomics Applications in Renal Tumor Assessment: A Comprehensive Review of the Literature. Cancers, 2020, 12, 1387.	3.7	33

#	Article	IF	CITATIONS
73	Preliminary evaluation of a novel sideâ€fire diode laser emitting light at 940 nm, for the potential treatment of benign prostatic hyperplasia: exâ€vivo and inâ€vivo investigations. BJU International, 2009, 103, 770-775.	2.5	32
74	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828.	5.0	32
75	Nonâ€Adrenergic, Tamsulosinâ€Insensitive Smooth Muscle Contraction is Sufficient to Replace α ₁ â€Adrenergic Tension in the Human Prostate. Prostate, 2017, 77, 697-707.	2.3	30
76	Radical cystectomy in the elderly patient: a contemporary comparison of perioperative complications in a single institution series. World Journal of Urology, 2010, 28, 445-450.	2.2	29
77	Localization and Function of Cannabinoid Receptors in the Corpus Cavernosum: Basis for Modulation of Nitric Oxide Synthase Nerve Activity. European Urology, 2010, 57, 342-349.	1.9	29
78	Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome. Urologia Internationalis, 2011, 86, 68-72.	1.3	29
79	Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. Journal of Endourology, 2016, 30, 792-798.	2.1	29
80	Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 728-738.	3.1	29
81	Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: Long-term follow-up. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 788-793.	1.6	27
82	Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. European Journal of Pharmacology, 2011, 650, 650-655.	3.5	27
83	Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2796-2803.	6.4	27
84	P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate. PLoS ONE, 2016, 11, e0153312.	2.5	26
85	The 1,318-nm diode laser supported partial nephrectomy in laparoscopic and open surgery: preliminary results of a prospective feasibility study. Lasers in Medical Science, 2011, 26, 689-697.	2.1	25
86	Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. American Journal of Physiology - Renal Physiology, 2014, 307, F823-F832.	2.7	25
87	A High-Fidelity Phantom for the Simulation and Quantitative Evaluation of Transurethral Resection of the Prostate. Annals of Biomedical Engineering, 2020, 48, 437-446.	2.5	25
88	The potential of CAR T cell therapy for prostate cancer. Nature Reviews Urology, 2021, 18, 556-571.	3.8	25
89	The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. American Journal of Physiology - Renal Physiology, 2013, 305, F1383-F1390.	2.7	24
90	A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT. Radiation Oncology, 2015, 10, 82.	2.7	24

#	Article	IF	CITATIONS
91	The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2057-2058.	6.4	23
92	Impact of Collateral Damage to Endourologic Tools During Laser Lithotripsy— <i>In Vitro</i> Comparison of Three Different Clinical Laser Systems. Journal of Endourology, 2011, 25, 667-672.	2.1	22
93	Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT. Strahlentherapie Und Onkologie, 2017, 193, 221-228.	2.0	22
94	Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU International, 2010, 106, 287-293.	2.5	21
95	Artificial Intelligence in Magnetic Resonance Imaging–based Prostate Cancer Diagnosis: Where Do We Stand in 2021?. European Urology Focus, 2022, 8, 409-417.	3.1	21
96	Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. British Journal of Pharmacology, 2018, 175, 2077-2096.	5.4	20
97	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	1.4	19
98	Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2. British Journal of Pharmacology, 2016, 173, 3342-3358.	5.4	19
99	Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. European Urology, 2019, 76, 767-779.	1.9	19
100	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers, 2021, 13, 5795.	3.7	19
101	Schwann cellâ€mediated delivery of glial cell lineâ€derived neurotrophic factor restores erectile function after cavernous nerve injury. International Journal of Urology, 2013, 20, 344-348.	1.0	18
102	Beta-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors. World Journal of Urology, 2011, 29, 157-163.	2.2	17
103	Contraction of the anterior prostate is required for the initiation of micturition. BJU International, 2013, 111, 1117-1123.	2.5	17
104	Postoperative upgrading of prostate cancer in men ≥75Âyears: a propensity score-matched analysis. World Journal of Urology, 2017, 35, 1517-1524.	2.2	17
105	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. European Urology Focus, 2018, 4, 369-375.	3.1	17
106	Current European Trends in Endoscopic Imaging and Transurethral Resection of Bladder Tumors. Journal of Endourology, 2020, 34, 312-321.	2.1	17
107	The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats. Neurourology and Urodynamics, 2014, 33, 1251-1258.	1.5	16
108	New strategies in treating male lower urinary tract symptoms. Current Opinion in Urology, 2014, 24, 29-35.	1.8	16

#	Article	IF	CITATIONS
109	Cooperative effects of EGF, FGF, and TGF- $\hat{1}^21$ in prostate stromal cells are different from responses to single growth factors. Life Sciences, 2015, 123, 18-24.	4.3	16
110	Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin – A multicenter study. Radiotherapy and Oncology, 2015, 116, 119-124.	0.6	16
111	A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. Journal of Biological Chemistry, 2019, 294, 12231-12249.	3.4	16
112	New strategies for inhibition of nonâ€adrenergic prostate smooth muscle contraction by pharmacologic intervention. Prostate, 2019, 79, 746-756.	2.3	16
113	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget, 2017, 8, 44131-44140.	1.8	16
114	Ho:YAG-laser: treatment of vesicourethral strictures after radical prostatectomy. World Journal of Urology, 2010, 28, 169-172.	2.2	15
115	Coupling of α ₁ -Adrenoceptors to ERK1/2 in the Human Prostate. Urologia Internationalis, 2011, 86, 427-433.	1.3	15
116	Virtual Reality Systems in Urologic Surgery: An Evaluation of the GreenLight Simulator. European Urology, 2013, 64, 687-688.	1.9	15
117	Cardiovascular Safety of the β ₃ â€Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. Journal of Clinical Pharmacology, 2018, 58, 1084-1091.	2.0	15
118	Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World Journal of Urology, 2015, 33, 917-922.	2.2	14
119	Dusting Efficiency of a Novel Pulsed Thulium:Yttrium Aluminum Garnet Laser <i>vs</i> a Thulium Fiber Laser. Journal of Endourology, 2022, 36, 259-265.	2.1	14
120	Safety and Efficacy of Laser Enucleation of the Prostate in Elderly Patients – A Narrative Review. Clinical Interventions in Aging, 2022, Volume 17, 15-33.	2.9	14
121	α1â€adrenoceptor activation induces phosphorylation of β2â€adrenoceptors in human prostate tissue. BJU International, 2011, 108, 922-928.	2.5	13
122	Laparoscopic Marsupialisation of Pelvic Lymphoceles in Different Anatomic Locations Following Radical Prostatectomy. European Urology, 2012, 62, 640-648.	1.9	13
123	Bladder function in a cannabinoid receptor type 1 knockout mouse. BJU International, 2014, 113, 144-151.	2.5	13
124	Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. European Journal of Pharmacology, 2017, 803, 39-47.	3.5	13
125	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2019, 2, 456-463.	5.4	13
126	Longâ€ŧerm treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourology and Urodynamics, 2019, 38, 779-792.	1.5	13

#	Article	IF	CITATIONS
127	Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats. Neurourology and Urodynamics, 2016, 35, 464-470.	1.5	12
128	Adherence to European Association of Urology and National Comprehensive Cancer Network Guidelines Criteria for Inguinal and Pelvic Lymph Node Dissection in Penile Cancer Patients—A Survey Assessment in German-speaking Countries on Behalf of the European Prospective Penile Cancer Study Group. European Urology Focus, 2021, 7, 843-849.	3.1	12
129	99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. EJNMMI Research, 2021, 11, 22.	2.5	12
130	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). International Journal of Radiation Oncology Biology Physics, 2022, 113, 1025-1035.	0.8	12
131	Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma. EAU-EBU Update Series, 2007, 5, 26-37.	0.6	11
132	Activation of protein kinase B/Akt by alpha1-adrenoceptors in the human prostate. Life Sciences, 2012, 90, 446-453.	4.3	11
133	Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005. Prostate, 2016, 76, 1364-1374.	2.3	11
134	Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. American Journal of Physiology - Renal Physiology, 2018, 314, F47-F57.	2.7	11
135	Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm. World Journal of Urology, 2021, 39, 2315-2327.	2.2	11
136	Current Disposable Ureteroscopes: Performance and Limitations in a Standardized Kidney Model. Journal of Endourology, 2020, 34, 1015-1020.	2.1	11
137	Inhibition of neurogenic and thromboxane A 2 â€induced human prostate smooth muscle contraction by the integrin α2β1 inhibitor BTTâ€3033 and the integrinâ€linked kinase inhibitor Cpd22. Prostate, 2020, 80, 831-849.	2.3	11
138	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. Frontiers in Oncology, 2020, 10, 246.	2.8	11
139	Inhibition of Female and Male Human Detrusor Smooth Muscle Contraction by the Rac Inhibitors EHT1864 and NSC23766. Frontiers in Pharmacology, 2020, 11, 409.	3.5	11
140	Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 782.e1-782.e5.	1.6	11
141	Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days' follow-up. Prostate Cancer and Prostatic Diseases, 2022, 25, 264-268.	3.9	11
142	Silodosin Inhibits Noradrenaline-Activated Transcription Factors Elk1 and SRF in Human Prostate Smooth Muscle. PLoS ONE, 2012, 7, e50904.	2.5	11
143	Noradrenaline induces binding of Clathrin light chain A to α1â€adrenoceptors in the human prostate. Prostate, 2013, 73, 715-723.	2.3	10
144	Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101. European Journal of Pharmacology, 2018, 831, 9-19.	3.5	10

#	Article	IF	CITATIONS
145	Efficacy and safety of aquablation of the prostate for patients with symptomatic benign prostatic enlargement: a systematic review. World Journal of Urology, 2020, 38, 1147-1163.	2.2	10
146	A novel endoimaging system for endoscopic 3D reconstruction in bladder cancer patients. Minimally Invasive Therapy and Allied Technologies, 2022, 31, 34-41.	1.2	10
147	Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries. Urologia Internationalis, 2020, 104, 410-416.	1.3	10
148	Radiation exposure during retrograde intrarenal surgery (RIRS): a prospective multicenter evaluation. World Journal of Urology, 2021, 39, 217-224.	2.2	10
149	Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms: A Markov Model–Based Cost-Effectiveness Analysis. Journal of the American College of Radiology, 2022, 19, 733-743.	1.8	10
150	Intermediate-differentiated invasive (pT1 G2) penile cancer—oncological outcome and follow-up. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 782-787.	1.6	9
151	Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU International, 2012, 110, E125-31.	2.5	9
152	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. Blood Pressure Monitoring, 2018, 23, 153-163.	0.8	9
153	Transient receptor potential a1 (<scp>TRPA1</scp>) agonists inhibit contractions of the isolated human ureter. Neurourology and Urodynamics, 2018, 37, 600-608.	1.5	9
154	Ghrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-14.	4.0	9
155	Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. European Urology Focus, 2022, 8, 794-802.	3.1	9
156	Incidental prostate cancer after holmium laser enucleation of the prostate—A narrative review. Andrologia, 2022, 54, e14332.	2.1	9
157	Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death. Prostate International, 2014, 2, 140-146.	2.3	8
158	Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases. Frontiers in Physiology, 2018, 9, 734.	2.8	8
159	Morcellation After Endoscopic Enucleation of the Prostate: Efficiency and Safety of Currently Available Devices. European Urology Focus, 2022, 8, 532-544.	3.1	8
160	Experimental ex-vivo performance study comparing a novel, pulsed thulium solid-state laser, chopped thulium fibre laser, low and high-power holmium:YAG laser for endoscopic enucleation of the prostate. World Journal of Urology, 2022, 40, 601-606.	2.2	8
161	Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Neurourology and Urodynamics, 2014, 33, 566-570.	1.5	7
162	The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade. World Journal of Urology, 2019, 37, 1103-1109.	2.2	7

#	Article	IF	CITATIONS
163	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	3.7	7
164	Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?. Prostate, 2021, 81, 377-389.	2.3	7
165	Comprehensive analysis of Twitter activity on #Incontinence. Neurourology and Urodynamics, 2020, 39, 440-446.	1.5	6
166	Diode laser treatment of human prostates – Clinical 6-month experience. Medical Laser Application: International Journal for Laser Treatment and Research, 2008, 22, 232-237.	0.3	5
167	Encrustation of urologic double pigtail catheters—an ex vivo optical coherence tomography (OCT) study. Lasers in Medical Science, 2013, 28, 919-924.	2.1	5
168	Are Over-the-Counter Alpha Blockers in the Best Interest of Men with Lower Urinary Tract Symptoms?. Urology Practice, 2017, 4, 395-404.	0.5	5
169	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinomaÂof the prostate. European Journal of Cancer, 2018, 95, 109-111.	2.8	5
170	Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI—A Correlation Study With Whole Mount Histopathological Information as Reference. Frontiers in Oncology, 2020, 10, 596756.	2.8	5
171	MRI phenotype of the prostate: Transition zone radiomics analysis improves explanation of prostate-specific antigen (PSA) serum level compared to volume measurement alone. European Journal of Radiology, 2020, 129, 109063.	2.6	5
172	Upper transverse scrotal approach for muscle- and nerve-sparing urethral stricture repair. World Journal of Urology, 2009, 27, 667-672.	2.2	4
173	Current pharmacological treatment options for male lower urinary tract symptoms. Expert Opinion on Pharmacotherapy, 2013, 14, 1043-1054.	1.8	4
174	Adrenoâ€muscarinic synergy in the male human urinary outflow tract. Neurourology and Urodynamics, 2018, 37, 2128-2134.	1.5	4
175	The new kids on the block. Current Opinion in Urology, 2018, 28, 294-300.	1.8	4
176	Patient Selection in Surgical Centers of Expertise in the Treatment of Patients with Moderate to Severe Male Urinary Stress Incontinence. Urologia Internationalis, 2020, 104, 902-907.	1.3	4
177	Preclinical and Clinical Evaluation of a Novel, Variable-View, Rigid Endoscope for Female Cystoscopy. Urology, 2020, 142, 231-236.	1.0	4
178	Metabolic Imaging of Urothelial Carcinoma by Simultaneous Autofluorescence Lifetime Imaging (FLIM) of NAD(P)H and FAD. Clinical Genitourinary Cancer, 2021, 19, e31-e36.	1.9	4
179	Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction. Life Sciences, 2021, 281, 119771.	4.3	4
180	Real-world data and treatment patterns of patients with lower urinary tract symptoms due to benign prostatic hyperplasia in Germany: an observational study using health insurance claims data. World Journal of Urology, 2021, 39, 4381-4388.	2.2	4

#	Article	IF	CITATIONS
181	Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer. Anticancer Research, 2021, 41, 3741-3746.	1.1	4
182	Effects of cavernous nerve reconstruction on expression of nitric oxide synthase isoforms in rats. BJU International, 2010, 106, 1726-1731.	2.5	3
183	Prostatic Urethral Lift Versus Transurethral Resection of the Prostate (TURP). Current Urology Reports, 2017, 18, 82.	2.2	3
184	Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?. Journal of Clinical Medicine, 2021, 10, 754.	2.4	3
185	Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series. European Urology Focus, 2021, , .	3.1	3
186	Evaluation of the Ginsburg Scheme: Where Is Significant Prostate Cancer Missed?. Cancers, 2021, 13, 2502.	3.7	3
187	Advances in Metabolic Imaging in Patients with Elevated Prostate Specific Antigen (PSA). EAU-EBU Update Series, 2006, 4, 20-32.	0.6	2
188	Risk Assessment and Medical Management of Acute Urinary Retention in Patients with Benign Prostatic Hyperplasia. EAU-EBU Update Series, 2006, 4, 109-116.	0.6	2
189	Daily Use of PDE5-Inhibitors: The Road to Happiness?. European Urology, 2008, 54, 28-30.	1.9	2
190	What Can Be Done to Maintain Men's Health: Perspectives from the EAU Young Academic Urologists Working Party Men's Health Group. European Urology, 2014, 66, 605-608.	1.9	2
191	Have We Really Abandoned Open Simple Prostatectomy Today?. European Urology, 2014, 66, 292-293.	1.9	2
192	Male Lower Urinary Tract Symptoms Reveal and Predict Important Cardiovascular Disease. European Urology, 2016, 70, 797-798.	1.9	2
193	Clinical Trials in Benign Prostatic Hyperplasia: A Moving Target of Success. European Urology Focus, 2019, 5, 1101-1104.	3.1	2
194	Re: Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. European Urology, 2020, 77, 559-560.	1.9	2
195	The complex genetics of epigenetics in urothelial carcinomas. Nature Reviews Urology, 2020, 17, 655-656.	3.8	2
196	Thermal effects of thulium: YAG laser treatment of the prostate—an in vitro study. World Journal of Urology, 2021, , 1.	2.2	2
197	Role of prostate specific antigen and prostate specific antigen density as biomarkers for medical and surgical treatment response in men with lower urinary tract symptoms. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 135-143.	3.9	2
198	More Than Detection of Adenocarcinoma – Indications and Findings in Prostate MRI in Benign Prostatic Disorders. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2022, , .	1.3	2

#	Article	IF	CITATIONS
199	Editorial Comment on: Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2009, 55, 591.	1.9	1
200	Anatomical description of the periprostatic nerves in the male rhesus monkey (Macaca mulatta). World Journal of Urology, 2011, 29, 375-380.	2.2	1
201	Onabotulinumtoxin A for Idiopathic Overactive Bladder: Raising the Bar. European Urology, 2012, 62, 158-159.	1.9	1
202	Re: Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 398.	1.9	1
203	Secondary Sling Implantation after Failure of Primary Surgical Treatment for Male Stress Urinary Incontinence: A Retrospective Study. Urologia Internationalis, 2020, 104, 625-630.	1.3	1
204	Feasibility of an Updated Randomised Controlled Trial on Surgical Urolithiasis Treatments: The Pilot Trial for the German Endoscopic versus Shock Wave Therapy Study (GESS). European Urology Focus, 2022, 8, 271-275.	3.1	1
205	Retrospective Evaluation of the Clinical Values of Minimally Invasive Marsupialization of Symptomatic Giant Renal Cysts. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2021, 31, 279-283.	1.0	1
206	Evaluation of functional parameters, patient-reported outcomes and workload related to continuous urinary bladder irrigation after transurethral surgery. Translational Andrology and Urology, 2021, 10, 2921-2928.	1.4	1
207	Robotic-assisted Excision of Giant Prostatic Utricular Cysts: Technique, Outcomes and Follow-up. Surgical Technology International, 2019, 35, 43-47.	0.2	1
208	Editorial Comment on: Diagnostic Accuracy of Noninvasive Tests to Evaluate Bladder Outlet Obstruction in Men: Detrusor Wall Thickness, Uroflowmetry, Postvoid Residual Urine, and Prostate Volume. European Urology, 2007, 52, 835.	1.9	0
209	Editorial Comment on: Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. European Urology, 2008, 54, 776-777.	1.9	0
210	Editorial Comment on: Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. European Urology, 2009, 55, 1448-1449.	1.9	0
211	Of Mice and Men: Animal Models in Functional Urology. European Urology, 2012, 62, 1086-1087.	1.9	Ο
212	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 2015, 67, 188-190.	1.9	0
213	Editorial Comment to Treatmentâ€related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology, 2016, 23, 1041-1042.	1.0	0
214	Minimally Invasive Treatment for Male Lower Urinary Tract Symptoms: the Prostatic Urethral Lift. Current Bladder Dysfunction Reports, 2016, 11, 134-139.	0.5	0
215	Reply to Matthew Bultitude and Pieter Le Roux's Letter to the Editor re: Jens SÃ,nksen, Neil J. Barber, Mark J. Speakman, et al. Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study. Eur Urol 2015:68:643–52. European Urology. 2016. 69. e39-e40.	1.9	0
216	Medical Treatment of Male Lower Urinary Tract Symptoms: Does One Fit All?. European Urology, 2017, 71, 582-583.	1.9	0

#	Article	IF	CITATIONS
217	All That Matters. European Urology Focus, 2017, 3, 517.	3.1	0
218	Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501–9. European Urology, 2019, 75, e59-e60.	1.9	0
219	Therapy-Refractory Matrix Staghorn in a Kidney Transplant Recipient: Endoscopic Percutaneous Morcellation as a Novel Treatment Option. Journal of Endourology Case Reports, 2020, 6, 209-212.	0.3	0
220	The transient receptor potential A1 ion channel (TRPA1) modifies in vivo autonomous ureter peristalsis in rats. Neurourology and Urodynamics, 2021, 40, 147-157.	1.5	0
221	Track and Teach: Identifying Key Movement Patterns in Endoscopic Transurethral Enucleation of the Prostate. Urologia Internationalis, 2021, 105, 835-845.	1.3	0
222	Data Mining in Urology: Understanding Real-world Treatment Pathways for Lower Urinary Tract Systems via Exploration of Big Data. European Urology Focus, 2022, , .	3.1	0
223	Temperature assessment study of ex vivo holmium laser enucleation of the prostate model. World Journal of Urology, 0, , .	2.2	0